# Formulation of the theoretical design

This document contains the extracted information for 30 out of the 66 articles included in the methodological review. It concerns here the 20 most recent articles (2015-2018) and 10 older articles (2005-2008). For every article we formulated a theoretical design which is written underneath the extracted information.

#### **Overview extracted information from articles:**

- 1. # (number of the article in the full table)
- 2. Reference (author)
- 3. Journal
- 4. Year of publication (YOP)
- 5. Impact factor (IF)
- 6. Title
- 7. Aim of the study
- 8. Domain and location in text
- 9. Outcome author
- 10. Measure of frequency for the outcome
- 11. Exposure author
- 12. Operationalization exposure
- 13. Measurement method exposure
- 14. Do the authors mention "(study) design" and where?
- 15. Design of data collection ( and where in text)
- 16. Design of data analysis
- 17. Measure of association (place in text & operationalization)
- 18. T0 (baseline, implicitly or explicitly mentioned?)
- 19. Confounders
- 20. Effect modifiers
- 21. Justification for the selection of confounders or effect modifiers
- 22. Referral to reporting guideline or theoretical work?

The theoretical design is formulated for every study. Sometimes two theoretical designs are possible, and in that case we mentioned them both in this document. We then selected the one which was the most inclusive (in bold and underlined).

#### List of abbreviations:

ABX	Antibiotics
BMI	Body Mass Index
ETS	Environmental tobacco smoke
HR	Hazard ratio
ICD	International classification of disease
ICS	Inhaled corticosteroids
ISAAC	International Study on Asthma and Allergies in Childhood
LRTI	Lower respiratory tract infection
NSAIDs	Non-steroidal anti-inflammatory drugs
OR	Odds ratio
RR	Rate ratio
RTI	Respiratory tract infection
SES	Socio economic status
URTI	Upper respiratory tract infection
UTI	Urinary tract infection

1. The effect of breastfeeding on the risk of asthma in high-risk children: a case-control study in Shanghai, China. Huo et al.

Number	1
Reference	Huo et al.
Journal	BMC pregnancy and childbirth
YOP	2018
IF	2.3
Title	The effect of breastfeeding on the risk of asthma in high-risk children: a
	case-control study in Shanghai, China
Aim	"to investigate the association between ABX use in pregnancy and the risk
	of childhood asthma, and the possible role of breast feeding in modulating
	the risks"
Domain	Children aged 3 to 12 years old (methods)
Outcome	Childhood asthma
Measure of frequency	/
Exposure	Maternal ABX use in pregnancy
Operationalization	Dichotomous (Yes/No)
exposure	
Measurement exposure	Face-to-face interview
"(Study) design"?	Yes (methods & discussion)
Data collection design	Case-control study (title and abstract)
	Hospital-based case-control study (methods and discussion)
	Retrospective study (discussion)
Data analysis design	Multiple logistic regression
Measure of association	OR (statistical analysis methods, categorical)
то	At 6 months of age (referred to as baseline, explicitly)
Confounders	Maternal age at delivery; maternal education level; child's age (not
	specified); child's gender; gestational age at birth; delivery mode; feeding
	status first 6 months of life (exclusive breastfeeding: yes/no); family history
	(allergic disorder: yes/no/unknown)
Effect modifiers	Child's age (not specified); child's gender; feeding status first 6 months of
	life (exclusive breastfeeding: yes/no); family history (allergic disorder:
	yes/no/unknown)
Justification selection	yes: previous publications
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	

# Theoretical design:

Future incidence of asthma onset as a function of baseline (at 6 months of age) exposure profile (maternal ABX exposure during pregnancy) in children aged 3 to 12 years adjusted for confounding by maternal age at delivery, delivery mode, child's gender, gestational age at birth, family history (allergic disorder: yes/no/unknown), maternal educational level, feeding status first 6 months of life (exclusive breastfeeding: yes/no), child's age (not specified) and for effect modification by child's gender, family history (allergic disorder: yes/no/unknown), feeding status first 6 months of life (exclusive breastfeeding: yes/no) and child's age (not specified).

2. Effects of antibiotics on the development of asthma and other allergic diseases in children and adolescents. Do Hyun Kim et al.

Number	2
Reference	Do Hyun Kim et al.
Journal	Allergy Asthma Immunol Res
YOP	2018
IF	3.8
Title	Effects of antibiotics on the development of asthma and other allergic
	diseases in children and adolescents
Aim	"determine if the duration of exposure to ABX in children and adolescents
	is associated with the later development of allergic disease."
Domain	Children and adolescents (title, introduction, methods, results & discussion)
Outcome	Asthma diagnosis
Measure of frequency	Incidence
Exposure	Duration of ABX exposure 7 years prior to development of allergic disease
Operationalization	Annual average ABX prescription days (6 categories)
exposure	
Measurement exposure	National Health Insurance (NHIS) database
"(Study) design"?	Yes (discussion)
Data collection design	Cross-sectional study (discussion)
Data analysis design	Multiple logistic regression
Measure of association	OR (tables and figures, 6 categories)
ТО	Onset asthma (the day allergic diseases were first diagnosed was set as an
	index date) or before the last day of 2015 (for controls) (explicitly)
Confounders	Age (at asthma diagnosis or inclusion as control); gender; number of days on
	which healthcare providers were visited (not specified when); income
	(insurance premium at onset asthma or before the last day of 2015); place
	of residence (at onset asthma or before the last day of 2015)
Effect modifiers	/
Justification selection	No
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	

## Theoretical design:

Current incidence of asthma onset as a function of baseline (asthma onset) exposure profile (exposure to ABX 7 years prior to the development of asthma) in children and adolescents adjusted for confounding by age (at asthma diagnosis or inclusion as a control), gender, number of days on which healthcare providers were visited (not specified when), income (insurance premium at onset asthma or before the last day of 2015), place of residence (at onset asthma or before the last day of 2015).

3. The current prevalence of asthma, allergic rhinitis, and eczema related symptoms in school-aged children in Costa Rica. Soto-Martínez et al.

Number	3
Reference	Soto-Martínez et al.
Journal	J asthma
YOP	2018
IF	2.0
Title	The current prevalence of asthma, allergic rhinitis, and eczema related symptoms in school-aged children in Costa Rica
Aim	"to study the current prevalence 12 years later in an inner-city group of children between 6 and 13 years old."
Domain	Children 6-13 years old (title, introduction, methods & discussion)
Outcome	Diagnosis of asthma (wheezing or whistling in the chest in the previous 12 months)
Measure of frequency	Prevalence
Exposure	ABX use in the first 12 months of life
Operationalization exposure	Dichotomous (Yes/No)
Measurement exposure	ISAAC questionnaires at 6-13 years of age
"(Study) design"?	Yes (discussion)
Data collection design	Cross-sectional study (abstract, discussion & conclusion)
Data analysis design	Poisson regression Multivariable analysis
Measure of association	OR (1 OR)
то	Onset asthma (implicitly)
Confounders	Complete set of confounders not specified, table 1 and table 3 include possibly a couple of confounders: rhinitis (ever); rhinitis (12 months before onset asthma); rhinoconjunctivitis (in the last 12 months); eczema ( yes/no, last 12 months); acetaminophen use (yes/no, first 12 months of life); traffic next to house (not specified); family member smoking at home (during the first year of life); wheezing chest after exercise (last 12 months); dry cough at night (last 12 months)
Effect modifiers Justification selection	Complete set of effect modifiers not specified, table 1 and table 3 include possibly a couple of effect modifiers: rhinitis (ever); rhinitis (12 months before onset asthma); rhinoconjunctivitis (in the last 12 months); eczema ( yes/no, last 12 months); acetaminophen use (yes/no, first 12 months of life); traffic next to house (not specified); family member smoking at home (during the first year of life); wheezing chest after exercise (last 12 months); dry cough at night (last 12 months) Explanation on how to check for confounding and effect modification in
confounders/effect modifiers?	statistical analysis part
Reporting guideline or theoretical work?	No

#### Theoretical design:

Current prevalence of asthma as a function of baseline exposure (asthma onset) profile (ABX use in the first 12 months of life) in children aged 6-13 years of age adjusted for confounding by rhinitis (ever), rhinitis (12 months before onset asthma), rhinoconjunctivitis (in the last 12 months), eczema ( yes/no, last 12 months), acetaminophen use (yes/no, first 12 months of life), traffic next to house (not specified), family member smoking at home (during the first year of life), wheezing chest after exercise (last 12 months), dry cough at night (last 12

months) and effect modification by rhinitis (ever), rhinitis (12 months before onset asthma), rhinoconjucntivitis (in the last 12 months), eczema ( yes/no, last 12 months), acetaminophen use (yes/no, first 12 months of life), traffic next to house (not specified), family member smoking at home (during the first year of life), wheezing chest after exercise (last 12 months), dry cough at night (last 12 months).

**COMMENT**: results section – B, theoretical design here: Prevalence of past exposure to antibiotics in the first 12 months of life as a function of current asthma status

# 4. Prenatal antibiotic exposure and childhood asthma: a population-based study. Loewen et al.

Number	4
Reference	Loewen et al.
Journal	Eur Respir J
YOP	2018
IF	12.2
Title	Prenatal antibiotic exposure and childhood asthma: a population-based study
Aim	"examining the association of maternal ABX use and childhood asthma"
Domain	Children (Introduction & methods)
Outcome	Child asthma = asthma after the age of 5: any hospitalization for asthma or at least 2 physician diagnosed asthma (at least 3 months apart and within 1 year) or at least 2 asthma medication prescriptions within 1 year
Measure of frequency	Incidence rate
Exposure	Maternal ABX use during pregnancy
Operationalization exposure	Dichotomous (Yes/No)
Measurement exposure	From database (prescriptions)
"(Study) design"?	Yes (methods)
Data collection design	Retrospective cohort study (methods)
	Population-based cohort study (discussion & abstract)
Data analysis design	Time-to-event analysis
	Cox regression
Measure of association	HR Incidence rate
ТО	Birth child (implicitly)
Confounders	Residence location (at birth); length of gestation (at birth); number of siblings (at birth); SES (at birth); infant gender; maternal asthma (at birth child); postnatal ABX exposure first year of life
Effect modifiers	Infant gender; method of birth; newborn feeding method
Justification selection	No
confounders/effect modifiers?	
Reporting guideline or	No
theoretical work?	

#### **Theoretical design:**

Future incidence of asthma onset as a function of baseline (at birth) exposure profile (maternal ABX use during pregnancy) in children adjusted for confounding by residence location (at birth), length of gestation (at birth), number of siblings (at birth), SES (at birth), infant gender, maternal asthma (at birth child), postnatal ABX exposure first year of life and effect modification by infant gender, method of birth and newborn feeding method.

5. Effect of antibiotic use for acute bronchiolitis on new-onset asthma in children. Lun-chen et al.

Number	5
Reference	Lun-chen et al.
Journal	Scientific Reports
ҮОР	2018
IF	4.1
Title	Effect of antibiotic use for acute bronchiolitis on new-onset asthma in
	children
Aim	<i>"to assess the relationship of early life ABX use for bronchiolitis with new-</i>
	onset asthma in children."
Domain	Children with a history of acute bronchiolitis in the first 2 years of life (title,
	introduction & discussion)
Outcome	New-onset asthma: ICD 9 criteria AND receipt of selective B2-agonist
	and/or ICS treatment twice within 1 year (age2-18)
Measure of frequency	/
Exposure	ABX dosage: ABX prescriptions (at least one ABX in the 5 years before the
	onset of asthma)
Operationalization	Cumulative defined daily dose (DDD) (3 categories)
exposure	Dichotomous (Yes/No)
Measurement exposure	Outpatient prescription database
"(Study) design"?	No
Data collection design	Matched case-control study (results)
Data analysis design	Conditional logistic regression
Measure of association	OR (methods, OR per category of ABX exposure)
то	Asthma onset (implicitly)
Confounders	urban residence (not specified); allergic rhinitis (not specified); atopic
	dermatitis (not specified); chronic rhinitis (not specified); age (at inclusion);
	acute sinusitis (not specified); gastroesophageal reflux (not specified); use
	of NSAIDs 120 days before asthma onset; gender; subtype of antibiotics
	(first 2 years of life)
Effect modifiers	age-stratified analysis
Justification selection	No
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	

#### Theoretical design:

Current incidence of asthma onset as a function of baseline (asthma onset) exposure profile (ABX use for acute bronchiolitis in the 5 years before the onset of asthma) in children with a history of acute bronchiolitis in the first 2 years of life adjusted for confounding by age (at inclusion), subtype of antibiotics (5 years prior to the onset of asthma), allergic rhinitis (not specified), atopic dermatitis (not specified), chronic rhinitis (not specified), acute sinusitis (not specified), gastroesophageal reflux (not specified), urban residence (not specified), use of NSAIDs (120 days before asthma onset), gender and effect modification by age.

6. Association between use of acid-suppressive medications and antibiotics during infancy and allergic diseases in early childhood. Mitre et al.

Number	6
Reference	Mitre et al.
Journal	JAMA Pediatrics
YOP	2018
IF	10.8
Title	Association between use of acid-suppressive medications and antibiotics during infancy and allergic diseases in early childhood
Aim	"to evaluate the hypothesis that exposure to either acid-suppressive medications or ABX during infancy is associated with an increased risk of childhood allergic disease"
Domain	Early childhood (introduction, methods, results & discussion)
Outcome	Asthma: after the age of 6 months (ICD)
Measure of frequency	Incidence
Exposure	ABX prescription at any time prior to the age of 6 months
Operationalization exposure	Categorical (cut off 10 days)
Measurement exposure	MHS (Tricare Management Activity Military Health System) prescription database
"(Study) design"?	Yes (abstract)
Data collection design	Retrospective cohort analysis (introduction) Retrospective cohort study (methods & discussion)
Data analysis design	Cox proportional hazards regression
Measure of association	HR (one hazard ratio, time-to-event analysis, methods)
то	At 6 months of age (implicitly)
Confounders	Prematurity; gender; caesarean delivery; other drug classes (first 6 months of life)
Effect modifiers	Any significant first order interaction terms; interaction with time
Justification selection confounders/effect modifiers?	Yes: publication on taking into account interaction with time
Reporting guideline or theoretical work?	No

## Theoretical design:

Future incidence of asthma onset after the age of 6 months as a function of baseline (at 6 months of age) exposure profile (ABX use at any time prior to the age of 6 months) in early childhood adjusted for confounding by prematurity, gender, caesarean delivery, other drug classes (first 6 months of life) and effect modification by any significant first order interaction terms (not specified) and time.

7. Prenatal and early-life antibiotic use and risk of childhood asthma: a retrospective cohort study. Yoshida et al.

Number	7
Reference	Yoshida et al.
Journal	Pediatr Allergy Immunol
YOP	2018
IF	4.1
Title	Prenatal and early-life antibiotic use and risk of childhood asthma: a
	retrospective cohort study
Aim	"evaluate the association between ABX exposure in early life and asthma
	development in childhood considering the types of ABX"
Domain	Children up to the age of 6 years (methods)
Outcome	Incidence of asthma: up to age 6 (diagnosis ICD & ICS and controllers use) ( at 12-35 months and 36-72 months of age)
Measure of frequency	Incidence
Exposure	Prescription of ABX to the mother during pregnancy or the child during the
	first year of birth
Operationalization	Dichotomous (Yes/No)
exposure	Type of ABX (4 categories)
	Number of ABX prescriptions (3 categories)
Measurement exposure	Large-scale claim database
"(Study) design"?	Yes ( introduction & methods)
Data collection design	Retrospective study (abstract)
	Retrospective cohort study (title & methods)
Data analysis design	Cox proportional hazards regression
Measure of association	HR (for every category of exposure)
то	At 12 months of age (explicitly)
Confounders	Gender; familial factors (by sibling analysis)
Effect modifiers	/
Justification selection	Yes: (9, 12) referred to studies using the same design to adjust for
confounders/effect	confounding
modifiers?	
Reporting guideline or	No
theoretical work?	

## **Theoretical design:**

The future incidence of asthma onset as a function of baseline (at 12 months of age) exposure profile (maternal exposure to ABX during pregnancy/Abx exposure in the first year of life) in children up to the age of 6 years adjusted for confounding by gender and familial factors (by sibling analysis).

8. Antibiotics in the first week of life were associated with atopic asthma at 12 years of age. Strömberg et al.

Number	8
Reference	Strömberg et al.
Journal	Acta Pediatrica
YOP	2018
IF	2.6
Title	Antibiotics in the first week of life were associated with atopic asthma at 12 years of age
Aim	"to examine the prevalence and risk factors for asthma at 12 years and to examine associations with atopic asthma and non-atopic asthma. In particular we wanted to analyze whether the long-term effects of ABX during the first week of life could be seen at age 12."
Domain	Children 12 years of age (methods)
Outcome	'Current' asthma at age 12 years:
	Atopic 'current' asthma at age 12
	Non-atopic 'current' asthma at age 12
Measure of frequency	Prevalence
Exposure	ABX treatment in the first week of life
Operationalization exposure	Dichotomous (Yes/No)
Measurement exposure	Questionnaire at 6 months of age
"(Study) design"?	No
Data collection design	Prospective birth cohort study (discussion)
Data collection design	Follow-up study (discussion)
Data analysis design	Multivariate logistic regression
Measure of association	OR (methods)
то	1 year of age/12 years of age (implicitly)
Confounders	maternal smoking during pregnancy; being born at <37 weeks gestation; any breast feeding for 4 months or longer; parental levels of education; parental asthma; being born small for gestational age; caesarian section; doctors-diagnosis of food allergy (first year of life); parental rhinitis, parental eczema; gender; maternal medication (during pregnancy); recurrent wheeze (first year of life); introduction of egg before 9 months of age; introduction of fish before 9 months of age; fish once a month or more in infancy; damp mould in the home (at 6 months of age); cat at home during infancy
Effect modifiers	
Justification selection confounders/effect modifiers?	No
Reporting guideline or theoretical work?	No

#### Theoretical design: 2 possibilities

Current prevalence of asthma ('current'/atopic 'current'/ non-atopic 'current') as a function of baseline (12 years of age) exposure profile (ABX exposure in the first week of life) in children 12 years of age adjusted for confounding by maternal smoking during pregnancy, being born at <37 weeks gestation, any breast feeding for 4 months or longer, parental levels of education, parental asthma, being born small for gestational age, caesarian section, doctors-diagnosis of food allergy (first year of life), parental rhinitis, parental eczema, gender, maternal medication (during pregnancy), recurrent wheeze (first year of life), introduction of egg before 9 months of age, introduction of fish before 9 months of age, fish once a month or more in infancy, damp mould in the home (at 6 months of age) and cat at home during infancy.

Future prevalence of asthma ('current'/atopic 'current'/ non-atopic 'current') as a function of baseline (at 1 year of age) exposure profile (ABX exposure in the first week of life) in children 12 years of age adjusted for confounding by maternal smoking during pregnancy, being born at <37 weeks gestation, any breast feeding for 4 months or longer, parental levels of education, parental asthma, being born small for gestational age, caesarian section, doctors-diagnosis of food allergy (first year of life), parental rhinitis, parental eczema, gender, maternal medication (during pregnancy), recurrent wheeze (first year of life), introduction of egg before 9 months of age, introduction of fish before 9 months of age, fish once a month or more in infancy, damp mould in the home (at 6 months of age) and cat at home during infancy. 9. Influence of antibiotic use in early childhood on asthma and allergic diseases at age 5. Yamamoto-Hanada et al.

Number	9
Reference	Yamamoto-Hanada et al.
Journal	Ann Allergy Asthma Immunol
YOP	2017
IF	3.2
Title	Influence of antibiotic use in early childhood on asthma and allergic diseases at age 5
Aim	"to elucidate the relation between postnatal ABX exposures within the first two years of life and allergic disease in children at 5 years of age"
Domain	Children 5 years of age (introduction & discussion)
Outcome	'Current' asthma (past 12 months) at 5 years of age
Measure of frequency	/
Exposure	History of ABX use (antibiotics ever in the first 2 years of life) and types of ABX used
Operationalization	Dichotomous (Yes/No)
exposure	Classes of ABX (4 categories)
Measurement exposure	Questionnaire at 2 years of age
"(Study) design"?	Yes ( discussion)
Data collection design	Hospital-based prospective birth cohort study (methods)
Data analysis design	Multivariate logistic regression
Measure of association	OR (per category of exposure, methods)
то	At 2 years of age (implicitly)
Confounders	maternal history of allergy; maternal age at pregnancy; maternal smoking during pregnancy; mode of delivery; gestational age at delivery; daycare attendance (during the first 2 years of life); number of previous live births; bronchitis (at 2 years of age); gender
Effect modifiers	/
Justification selection confounders/effect modifiers?	No
Reporting guideline or theoretical work?	No

## Theoretical design:

Future prevalence of 'current' asthma as a function of baseline (at 2 years of age) exposure profile (use of ABX in the first two years of life) in children 5 years of age adjusted for confounding by maternal history of allergy, maternal age at pregnancy, maternal smoking during pregnancy, mode of delivery, gestational age at delivery, daycare attendance (during the first 2 years of life), number of previous live births, bronchitis (at 2 years of age) and gender.

# 10. Early life antibiotic use and the risk of asthma and asthma exacerbations in children. Ahmadizar et al.

Number	10
Reference	Ahmadizar et al.
Journal	Pediatr Allergy Immunol
YOP	2017
IF	4.1
Title	Early life antibiotic use and the risk of asthma and asthma exacerbations in
	children
Aim	"evaluate the effect of early life ABX use on the risk of asthma onset later
	in life in the general population. Moreover, in the pediatric population with
	asthma, the association between early life ABX use and the risk of asthma
	exacerbations later in life was studied."
Domain	Children (Generation R and Seaton)
	Children with asthma (Pacman and Breathe)
Outcome	Physician diagnosed asthma and asthma exacerbations:
	Generation R: ever asthma? Confirmed by doctor? (age 9-10) Seaton: ever
	asthma? Confirmed by doctor? (age 10)
	PACMAN: asthma exacerbations in the past 12 months (age 4-12 years)
	(emergency department visits, oral corticosteroids)
	BREATHE: : asthma exacerbations in the past 6 months (age 3-19 years)
Measure of frequency	Prevalence rate
_	Cumulative incidence rate
Exposure	Antibiotics use (all 4 cohorts)
	Timing of ABX use (Generation R, Pacman and Breathe)
	Number of prescriptions during first 3 years of life (Pacman and Breathe)
	Total days of exposure to ABX in the first 3 years of life (Pacman and Breathe)
Operationalization	Dichotomous (exposed vs. never exposed)
exposure	Timing first ABX use (1st, 2nd, 3rd year of life) (GENERATION R, PACMAN &
exposure	BREATHE)
	Number of prescriptions during first 3 years (PACMAN & BREATHE) (and
	total days of exposure)
Measurement exposure	Generation R: parental questionnaire at 1, 2 and 3 years
·	Seaton: first 6 months parent-reported
	Pacman & Breathe: pharmacy data from first year of life
"(Study) design"?	Yes (methods & discussion)
Data collection design	2 population based cohorts (abstract & methods)
	2 asthma cohorts (abstract)
Data analysis design	Multivariable logistic regression
	Meta-analysis
Measure of association	OR (methods, OR per category of ABX exposure)
то	Generation R: at 1 year of age
	Seaton: at 6 months of age
	Pacman & Breathe: asthma onset
	(implicitly)
Confounders	Generation R, Pacman and Breathe: age (not specified); gender; family
	history of asthma or allergy
	Seaton: gender; family history of asthma or allergy
Effect modifiers	Age-stratified analysis
Justification selection	No, based on available variables in the database
confounders/effect	
modifiers?	

Reporting guideline or	No
theoretical work?	

#### **Theoretical design:**

#### **Generation R:**

Future prevalence of asthma as a function of baseline (at 1 year of age) exposure profile (ABX use ever/ABX use in the first year of life/2<sup>nd</sup> year of life/3<sup>rd</sup> year of life) in children adjusted for confounding by age (not specified), gender, family history of asthma or allergy and effect modification by age.

#### Seaton:

Future prevalence of asthma as a function of baseline (at 6 months of age) exposure profile (ABX use ever/ABX use in the first 6 months of life) in children adjusted for confounding by, gender and family history of asthma or allergy.

#### Pacman & Breathe:

Future prevalence of asthma exacerbations as a function of baseline (asthma onset) exposure profile (ABX use in the first 3 years of life) in children with asthma adjusted for confounding by age (not specified), gender, family history of asthma and effect modification by age.

Number	11
Reference	Kashanian et al.
Journal	Int J Gynecol Obstet
ҮОР	2017
IF	2.0
Title	Evaluation of the associations between childhood asthma and prenatal and perinatal factors
Aim	"to identify prenatal and perinatal risk factors of childhood asthma."
Domain	Children aged 7-14 years (methods)
Outcome	Diagnosis of asthma (age 7-14 years)
Measure of frequency	
Exposure	Not specified in methods
	In tables: ABX during pregnancy
Operationalization	Dichotomous (Yes/No)
exposure	
Measurement exposure	Maternal data sheets from hospitals where children were delivered
"(Study) design"?	Yes (discussion)
Data collection design	Retrospective case-control study (abstract & methods)
Data analysis design	Forward logistic regression
	Multivariate regression analysis
Measure of association	OR (table, one OR given for ABX exposure)
то	Asthma prevalence diagnosis/birth child (implicitly)
Confounders	Matched for age and gender; maternal history of asthma; vaginal bleeding
	during pregnancy; maternal age >= 30; exclusive breastfeeding (neonatally)
Effect modifiers	/
Justification selection	No
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	

**11.** Evaluation of the associations between childhood asthma and prenatal and perinatal factors. Kashanian et al.

Theoretical design: 2 possibilities

<u>Current prevalence of asthma as a function of baseline (asthma prevalence diagnosis)</u> exposure profile (maternal ABX use during pregnancy) in children aged 7-14 years adjusted for confounding by age (occurrence of asthma or inclusion as control, matching cases and control), gender, maternal history of asthma, vaginal bleeding during pregnancy, maternal age >= 30 and exclusive breastfeeding (neonatally).

Future prevalence of asthma as a function of baseline (at birth) exposure profile (maternal ABX use during pregnancy) in children aged 7-14 years adjusted for confounding by age (occurrence of asthma or inclusion as control, matching cases and control), gender, maternal history of asthma, vaginal bleeding during pregnancy, maternal age >= 30 and exclusive breastfeeding (neonatally).

12. Antibiotic use in early life, rural residence, and allergic diseases in Argentinean children. Han et al.

Number	12
Reference	Han et al.
Journal	J Allergy Clin Immunol Pract
YOP	2017
IF	6.96
Title	Antibiotic use in early life, rural residence, and allergic diseases in Argentinean children
Aim	"examine the relation between antibiotics use in early life and current asthma among children aged 6 to 7 years"
Domain	Children aged 6 to 7 years (title, introduction, methods & discussion)
Outcome	'Current' asthma: parental report of physician diagnosed asthma and 'current' wheeze (in previous year)
Measure of frequency	/
Exposure	Any use of ABX in the first year of life
Operationalization exposure	Dichotomous (Yes/No)
Measurement exposure	Spanish ISAAC questionnaire distributed at school for parents of 6-7 year old children
"(Study) design"?	Yes (methods & discussion)
Data collection design	Cross-sectional study (abstract)
Data analysis design	Multivariate logistic regression Multivariable analysis
Measure of association	OR (methods, one odds ratio)
то	At the end of the first year of life / 6-7 years of age (implicitly)
Confounders	Age (at inclusion in study); gender; parental history of allergy; paracetamol use first year of life; bronchiolitis first year of life; consumption of unpasteurized milk (first year of life)
Effect modifiers	Rural residence in the first year of life
Justification selection confounders/effect modifiers?	Νο
Reporting guideline or theoretical work?	No

Theoretical design: 2 possibilities

<u>Current prevalence of 'current' asthma as a function of baseline (6-7 years of age) exposure</u> profile (ABX use in the first year of life) in children aged 6-7 years adjusted for confounding by age (at inclusion in study), gender, parental history of allergy, paracetamol use (first year of life), bronchiolitis (first year of life), consumption of unpasteurized milk (first year of life) and effect modification by residence type (rural or urban) in the first year of life.

**Future prevalence of 'current' asthma** as a function of function of baseline (at the end of the first year of life) exposure profile (ABX use in the first year of life) in children aged 6-7 years adjusted for confounding by age (at inclusion in study), gender, parental history of allergy, paracetamol use (first year of life), bronchiolitis (first year of life), consumption of unpasteurized milk (first year of life) and effect modification by residence type (rural or urban) in the first year of life.

Number	13
Reference	Gupta et al.
Journal	Allergy Asthma Proc
YOP	2016
IF	2.6
Title	Hygiene factors associated with childhood food allergy and asthma
Aim	"to assess whether hygiene factors are associated with a food allergy
<u> </u>	and/or asthma diagnosis. We investigated key hygiene factors, including
	ABX use, and their association with food allergy and asthma"
Domain	Children aged 0-21 years (abstract & methods)
Outcome	Asthma: physician diagnosis of asthma (0-21 years) (current)
Measure of frequency	Prevalence
Exposure	ABX use in the first year of life
Operationalization	Dichotomous (Yes/No)
exposure	
Measurement exposure	Questionnaire at the time of inclusion
"(Study) design"?	Yes (introduction)
Data collection design	Cross-sectional family-based study (abstract)
Data analysis design	Poisson regression model
Measure of association	Prevalence ratio's (per category of exposure, methods)
то	Inclusion in study (asthma occurrence, implicitly)
Confounders	parent reported infections (first year of life); eczema (overall); age (at
	inclusion in the study); household income (unspecified); number of siblings
	(current); child care (first 5 years of life); race; sex; pets (first year of life);
	parental atopy; breast feeding
Effect modifiers	/
Justification selection	No
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	

# Theoretical design:

Current prevalence of asthma as a function of baseline (at inclusion in study) exposure profile (ABX use in the first year of life) in children aged 0-21 years adjusted for confounding by parent reported infections (first year of life), eczema (overall), age (at inclusion in the study), household income (unspecified), number of siblings (current), child care (first 5 years of life), race, sex, pets (first year of life), parental atopy and breast feeding.

# 14. Antibiotic use during pregnancy and asthma in preschool children: the influence of confounding. Mulder et al.

Number	14
Reference	Mulder et al.
Journal	Clinical & Experimental Allergy
YOP	2016
IF	5.2
Title	Antibiotic use during pregnancy and asthma in preschool children: the influence of confounding
Aim	"to assess the association between ABX use in pregnancy and the development of asthma in preschool children, to evaluate the influence of confounding, results of the case-sibling analysis were compared with results
	obtained using a matched case-control design. In addition, we evaluated the influence of potential time trends in exposure frequencies in the case- sibling analysis."
Domain	Preschool children up to the age of 5 years (introduction, methods & discussion)
Outcome	Asthma: at least 3 prescriptions for asthma medication within a 12 month period before the 5 <sup>th</sup> birthday
Measure of frequency	/
Exposure	Maternal exposure to ABX: at least 1 day supply of systemic ABX during
	pregnancy
Operationalization	Dichotomous (Yes/No)
exposure	Per trimester of exposure
	Per subgroup of ABX (5 classes)
Measurement exposure	Prescription database
"(Study) design"?	Yes (introduction, methods, results, discussion & appendix)
Data collection design	Case-sibling study (abstract, introduction & results)
_	Nested case-sibling study (methods)
	Case-sibling analysis(discussion)
	Case-control study (abstract)
	Case-control analysis (results & discussion)
	Matched case-control design (introduction & methods)
Data analysis design	Conditional logistic regression
Measure of association	OR (for every exposure class, methods & results)
то	Birth child (implicitly)
Confounders	Gender; age at delivery; use of acid-suppressive drugs (during pregnancy);
	use of drugs indicated for allergic dermatitis (during pregnancy); use of
	drugs indicated for allergic rhinitis (during pregnancy); use of insulin (during
	pregnancy); potential time trends (in the case-sibling analysis); child birth
	order; use of asthma medication (during pregnancy); use of
	antidepressants (during pregnancy)
Effect modifiers	/
Justification selection	Yes: publication
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	
theoretical work?	

# Theoretical design:

Current prevalence of asthma as a function of baseline (birth child) exposure profile (maternal exposure to ABX during pregnancy) in preschool children up to the age of 5 years

adjusted for confounding by gender, age at delivery, use of acid-suppressive drugs (during pregnancy), use of drugs indicated for allergic dermatitis (during pregnancy); use of drugs indicated for allergic rhinitis (during pregnancy), use of insulin (during pregnancy), child birth order, use of asthma medication (during pregnancy), use of antidepressants (during pregnancy) and potential time trends (in the case-sibling analysis only).

15. Relative importance and additive effects of maternal and infant risk factors on childhood	
asthma. Wu et al.	

Number	15
Reference	Wu et al.
Journal	Plos One
YOP	2016
IF	2.8
Title	Relative importance and additive effects of maternal and infant risk factors on childhood asthma
Aim	"to determine the relative impact and cumulative effect of in utero, perinatal and postnatal exposures that could be measured during pregnancy and infancy on the risk of developing early childhood asthma: maternal ABX use/urinary tract infection (UTI), mode of delivery, infant ABX use, and having older siblings. We also assessed the dose-dependent relationship of maternal ABX use/UTI, infant ABX use, and number of older siblings on the risk of developing early childhood asthma."
Domain	Children aged 4.5 to 6 years (methods & results)
Outcome	Childhood asthma: ascertained between 4,5 and 6 years: ICD9 diagnosis or prescriptions for any short-acting $\beta$ -agonist, 2 prescriptions for montelukast in a 365-day period, or a single prescription of any other asthma-specific medication
Measure of frequency	/
Exposure	ABX use during infancy (first 12 months) ABX use during pregnancy
Operationalization	Number of courses of ABX (9 categories, from 0 to more than 8 doses for
exposure	ABX use in infancy and 6 categories for ABX use during pregnancy)
Measurement exposure	Infant ABX use: medical claims prescription fill data
	Mothers: TennCare insurance
"(Study) design"?	No
Data collection design	Population-based birth cohort study (abstract, methods & discussion)
Data analysis design	Multivariable logistic regression model
Measure of association	OR (for every category OR, 0 courses as reference)
то	Age 1 / age 5 (implicitly)
Confounders	Maternal smoking during pregnancy; maternal asthma status; maternal age at delivery; maternal educational level; gestational age at delivery; infant's birth hospitalization length of stay; birth weight; infant's race; gender; having chronic lung disease (not specified); having congenital heart disease (not specified); type of most severe bronchiolitis healthcare encounters experienced during infancy; birth year; study site
Effect modifiers	Subgroup analysis: birth weight, KPNC (Kaiser Permanente Northern California) or TennCare (Tennesee Medicaid program)
Justification selection confounders/effect modifiers?	Yes: covariates chosen a priori based on clinical relevance
Reporting guideline or theoretical work?	/

# Theoretical design: 2 possibilities

Future prevalence of asthma as a function of baseline (age 1) exposure profile (ABX use during the first 12 months of life / maternal ABX use during pregnancy) in children aged 4.5 to 6 years adjusted for confounding by maternal smoking during pregnancy, maternal asthma

status, maternal age at delivery, maternal educational level, gestational age at delivery, infant's birth hospitalization length of stay, birth weight, infant's race, gender, having chronic lung disease (not specified), having congenital heart disease (not specified), type of most severe bronchiolitis healthcare encounters experienced during infancy, birth year, study site and effect modification by birth weight.

<u>Current prevalence of asthma as a function of baseline (age 5) exposure profile (ABX use in the first 12 months of life / maternal ABX use during pregnancy) in children aged 4.5 to 6 years adjusted for confounding by maternal smoking during pregnancy, maternal asthma status, maternal age at delivery, maternal educational level, gestational age at delivery, infant's birth hospitalization length of stay, birth weight, infant's race, gender, having chronic lung disease (not specified), having congenital heart disease (not specified), type of most severe bronchiolitis healthcare encounters experienced during infancy, birth year, study site and effect modification by birth weight.</u>

16. Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Korpela et al.

Number	16
Reference	Korpela et al.
Journal	Nature Communications
YOP	2016
IF	12.1
Title	Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-
	school children
Aim	"to investigate the short- and long-term effects of ABX on preschool
	children's intestinal microbiome and health."
Domain	Children aged 2-7 years (title, introduction, results & methods)
Outcome	Diagnosed asthma: current or developing asthma (age 2-7 years)
Measure of frequency	/
Exposure	Overall lifetime ABX use: macrolide use during the first 2 years of life
Operationalization	Dichotomous (more than 2 courses of macrolides in the first 2 years of life
exposure	vs. non-exposed)
Measurement exposure	National database on prescription drug purchase
"(Study) design"?	No
Data collection design	Cohort (introduction, results, discussion & methods)
Data analysis design	Fisher's test
Measure of association	OR for the group that used more than 2 courses of macrolides in the first
	two years of life
то	Asthma diagnosis / at 2 years of age (implicitly)
Confounders	/
Effect modifiers	/
Justification selection	No
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	

Theoretical design: 2 possibilities

<u>Current prevalence of asthma as a function of baseline (asthma diagnosis) exposure status</u> (macrolide use during the first 2 years of life) in children aged 2-7 years.

Future prevalence of asthma as a function of baseline (at 2 years of age) exposure profile (macrolide use during the first 2 years of life) in children aged 2-7 years.

Number	17
Number	17
Reference	Chu et al.
Journal	Plos One
YOP	2015
IF	3.0
Title	Periconceptional and gestational exposure to antibiotics and childhood
	asthma
Aim	"to assess the associations between maternal exposure to different types
	of ABX before and during pregnancy and childhood asthma"
Domain	Children up to the age of 7 years (introduction & methods)
Outcome	Definite asthma by 7 years of age: medical records
Measure of frequency	Prevalence
Exposure	Maternal ABX exposure: ABX by oral or injection during 4 weeks prior to
	last menstrual period or at any month during pregnancy
Operationalization	6 categories of ABX subdivided in 5 categories for timing of exposure (total
exposure	exposure, 4 week before last menstrual period, 1 <sup>st</sup> trimester, 2 <sup>nd</sup> trimester
	and 3 <sup>rd</sup> trimester)
Measurement exposure	Questionnaires during pregnancy
"(Study) design"?	No
Data collection design	Prospective cohort study? (discussion)
Data analysis design	Multilevel multiple logistic regression
Measure of association	OR (per category of exposure, methods)
то	Birth child / 7 years of age (implicitly)
Confounders	maternal age at delivery; race (mother); number of previous births;
	smoking during pregnancy; maternal drug allergy history; married at
	pregnancy; educational level; maternal asthma history
Effect modifiers	stratification by time of medication (not explicitly)
Justification selection	Yes: previous publication
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	

#### 17. Periconceptional and gestational exposure to antibiotics and childhood asthma. Chu et al.

#### Theoretical design: 2 possibilities

Future prevalence of asthma as a function of baseline (birth child) exposure profile (maternal exposure to ABX 4 weeks prior to the last menstrual period or at any time during pregnancy) in children up to the age of 7 years adjusted for confounding by maternal age at delivery, race (mother), number of previous births, smoking during pregnancy, maternal drug allergy history, married at pregnancy, educational level, maternal asthma history (and effect modification by timing of medication?).

<u>Current prevalence of asthma as a function of baseline (at 7 years of age) exposure profile</u> (maternal exposure to ABX 4 weeks prior to the last menstrual period or at any time during pregnancy) in children up to the age of 7 years adjusted for confounding by maternal age at delivery, race (mother), number of previous births, smoking during pregnancy, maternal drug allergy history, married at pregnancy, educational level, maternal asthma history (and effect modification by timing of medication?). 18. Antibiotic exposure in the first year of life and later treated asthma, a population based birth cohort study of 143000 children. Pitter et al.

Number	18
Reference	Pitter et al.
Journal	Eur J Epidemiol
YOP	2015
IF	7.1
Title	Antibiotic exposure in the first year of life and later treated asthma, a
	population based birth cohort study of 143000 children
Aim	"to evaluate whether exposure to ABX during the first 12 months of life
	increases the risk of subsequent treated asthma"
Domain	Children up to the age of 17 years (title, introduction, methods, results & discussion)
Outcome	Treated asthma: at least 2 prescriptions at different time points within a 12
	months period, of anti-asthmatic drugs
	'Current' asthma at age 6 years or older and at age 13 years or older
Measure of frequency	Incidence rate ratio
Exposure	ABX exposure during the first 12 months of life: prescription of at least 1
	antibiotic
Operationalization	Dichotomous, ABX ever (Yes/No)
exposure	Number of courses (4 categories)
	Penicillins (Yes/No)
	Cephalosporins (Yes/No)
	Macrolides (Yes/No)
	Other drugs (Yes/No)
Measurement exposure	Drug prescription records
"(Study) design"?	Yes (discussion & introduction)
Data collection design	Population-based birth cohort study (abstract & discussion)
Data analysis design	Poisson models
Measure of association	Incidence rate ratio's (for every category, methods)
ТО	At 13 months of age (explicitly)
Confounders	year of birth; maternal age at birth; gestational age; type of delivery; sex;
	mother's formal education; birth weight; RTI requiring hospital admission
	during the first 12 months of life (confounding by indication)
Effect modifiers	/
Justification selection	No
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	

# Theoretical design:

Future incidence of asthma onset/'current' asthma onset at age 6 years or older/'current' asthma onset at age 13 years or older as a function of baseline (at 13 months of age) exposure profile (ABX use during the first 12 months of life) in children up to the age of 17 years adjusted for confounding by year of birth, maternal age at birth, gestational age, type of delivery, sex, mother's formal education, birth weight, RTI requiring hospital admission during the first 12 months of life (confounding by indication).

19. Association between antibiotic exposure, bronchiolitis, and TLR4 (rs1927911) polymorphisms in childhood asthma. Lee et al.

Number	19
Reference	Lee et al.
Journal	Allergy Asthma Immunol Res
YOP	2015
IF	2.3
Title	Association between antibiotic exposure, bronchiolitis, and TLR4
	(rs1927911) polymorphisms in childhood asthma
Aim	"investigate the risk factors involved in the development of asthma during
	early life and their interactions. Specifically, we investigated whether ABX
	exposure in the first year of life and a history of physician diagnosed
	bronchiolitis in the first 2 years of life were associated with an increased risk
	of childhood asthma. In addition, we evaluated whether a polymorphism in
	TLR4 (rs1927911) modulates the impact of these environmental factors"
Domain	Children (methods, results & discussion)
Outcome	Prevalence of asthma: ever been diagnosed with asthma
Measure of frequency	Prevalence
Exposure	ABX exposure in the first year of life
Operationalization	Dichotomous (Yes/no)
exposure	
Measurement exposure	Modified version of the ISAAC questionnaire
"(Study) design"?	No
Data collection design	Cross-sectional study (abstract & discussion)
Data analysis design	Logistic regression
Measure of association	OR (OR for ABX exposure category yes vs. no, methods)
то	Inclusion in study ( implicitly)
Confounders	Age (at inclusion); BMI (at inclusion); household income (at inclusion);
	parental history of allergic disease; sex; school area; ETS (at inclusion)
Effect modifiers	stratification by genotype TLR4: modifies combined effect of infant ABX
	exposure in the first year of life and history of physician diagnosed
	bronchiolitis in the first 2 years of life on the development of asthma
Justification selection	No
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	

# Theoretical design:

Current prevalence of asthma as a function of baseline (inclusion in study) exposure profile (ABX use in the first year of life) in children adjusted for confounding by age (at inclusion), BMI (at inclusion), household income (at inclusion), parental history of allergic disease, sex, school area, ETS (at inclusion) and effect modification by genotype TLR4.

NumericLapin et al.JournalAnn Allergy Asthma ImmunolYOP2015IF3.4TitleThe relationship between prenatal antibiotic use and asthma in at-risk childrenAim"we investigated the effects of prenatal ABX use with the subsequent development of asthma by year 3 and wheezing in the third year"DomainAt-risk children up to the age of 3 years (title & discussion)OutcomeAstma: Asthma diagnosis by year 3 (ever having asthma) (diagnosis by a physician, parent-reported)Measure of frequencyIncidenceExposureSystemic ABX us: antibiotic use during pregnancyOperationalizationPrenatal ABX use: dichotomous (yes/no) (any ABX during pregnancy) exposureMeasurement exposureQuestionnaires"(Study) design"?Yes (discussion) Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)TOAt 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; waternal age; smoking during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of life; any respiratory infections during the child's first year of life; any respiratory infections during the child's first year of life; any ibuprofen use of the child in the first year of life life; any respiratory infections during the child's first year of life; any respiratory infections during the child's first year of life; any respiratory infections during the chil	Number	20
JournalAnn Allergy Asthma ImmunolYOP2015IF3.4TitleThe relationship between prenatal antibiotic use and asthma in at-risk childrenAim"we investigated the effects of prenatal ABX use with the subsequent development of asthma by year 3 and wheezing in the third year"DomainAt-risk children up to the age of 3 years (title & discussion)OutcomeAsthma: Asthma diagnosis by year 3 (ever having asthma) (diagnosis by a physician, parent-reported)Measure of frequencyIncidenceExposureSystemic ABX us: antibiotic use during pregnancyOperationalizationPrenatal ABX use: dichotomous (yes/no) (any ABX during pregnancy)exposureTiming of ABX use (first trimester vs. second and third trimester)Measure of associationQuestionnaires"(Study) design"?Yes (discussion)Data collection designMultivariable logistic regressionMeasure of associationOR (results, per category)T0At 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); biuprofen use during pregnancy; maternal age; smoking during pregnancy; exposure to smoke in the home in the first year of life; child antibiotic use of the child in the first year of lifeEffect modifiersVitamin use of the child in the first year of lifeIffer, child antibiotic use of the child in the first year of lifeStudy in the home during pregnancy; maternal history of asthma; any ibuprofen use of the child is first year of lifeIffect modifiers?No		
YOP         2015           IF         3.4           Title         The relationship between prenatal antibiotic use and asthma in at-risk children           Aim         "we investigated the effects of prenatal ABX use with the subsequent development of asthma by year 3 and wheezing in the third year"           Domain         At-risk children up to the age of 3 years (title & discussion)           Outcome         Asthma: Asthma diagnosis by year 3 (ever having asthma) (diagnosis by a physician, parent-reported)           Measure of frequency         Incidence           Exposure         Systemic ABX us: antibiotic use during pregnancy           Operationalization         Prenatal ABX use: dichotomous (yes/no) (any ABX during pregnancy)           exposure         Timing of ABX use (first trimester vs. second and third trimester)           Measurement exposure         Questionnaires           "(Study) design"?         Yes (discussion)           Prospective study (Introduction)         Data analysis design           Multivariable logistic regression         Measure of association           OR (results, per category)         TO           Confounders         Study intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; exposure to smoke in the home in the first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; maternal		•
IF       3.4         Title       The relationship between prenatal antibiotic use and asthma in at-risk children         Aim       "we investigated the effects of prenatal ABX use with the subsequent development of asthma by year 3 and wheezing in the third year"         Domain       At-risk children up to the age of 3 years (title & discussion)         Outcome       Asthma: Asthma diagnosis by year 3 (ever having asthma) (diagnosis by a physician, parent-reported)         Measure of frequency       Incidence         Exposure       Systemic ABX use: antibiotic use during pregnancy         Operationalization       Prenatal ABX use: dichotomous (yes/no) (any ABX during pregnancy)         riming of ABX use (first trimester vs. second and third trimester)         Measurement exposure       Questionnaires         "(Study) design"?       Yes (discussion)         Prospective study (Introduction)       Prospective study (Introduction)         Data collection design       Multivariable logistic regression         Measure of association       OR (results, per category)         TO       At 1 year of age (implicitly)         Confounders       Study intervention; maternal history of asthma; maternal ethnicitly (Mexican ancestry); ibuprofen use during pregnancy; witamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of life; smoking in the home during the child's first yea		
TitleThe relationship between prenatal antibiotic use and asthma in at-risk childrenAim"we investigated the effects of prenatal ABX use with the subsequent development of asthma by year 3 and wheezing in the third year"DomainAt-risk children up to the age of 3 years (title & discussion)OutcomeAsthma: Asthma diagnosis by year 3 (ever having asthma) (diagnosis by a physician, parent-reported)Measure of frequencyIncidenceExposureSystemic ABX us: antibiotic use during pregnancyOperationalizationPrenatal ABX use: dichotomous (yes/no) (any ABX during pregnancy) Timing of ABX use (first trimester vs. second and third trimester)Measurement exposureQuestionnaires (Study) design"?Ves (discussion) Prospective study (Introduction)Other (discussion) Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)TOAt 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of life? Sind use of the mother during pregnancy interval history of asthma; any ibuprofen use of the child in the first year of lifeJustification selection confounders/effect modifiers?NoReporting guideline orNo		
AimchildrenAim"we investigated the effects of prenatal ABX use with the subsequent development of asthma by year 3 and wheezing in the third year"DomainAt-risk children up to the age of 3 years (title & discussion)OutcomeAsthma: Asthma diagnosis by year 3 (ever having asthma) (diagnosis by a physician, parent-reported)Measure of frequencyIncidenceExposureSystemic ABX us: antibiotic use during pregnancyOperationalizationPrenatal ABX use: dichotomous (yes/no) (any ABX during pregnancy) Timing of ABX use (first trimester vs. second and third trimester)Measurement exposureQuestionnaires"(Study) design"?Yes (discussion) Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)TOAt 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; any ibuprofen use during the child's first year of life; sind antibiotic use of respiratory reasons, vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life? Sind year of life; respiratory infections during the child's first year of lifeIffect modifiers?NoReporting guideline orNo		
Aim"we investigated the effects of prenatal ABX use with the subsequent development of asthma by year 3 and wheezing in the third year"DomainAt-risk children up to the age of 3 years (title & discussion)OutcomeAsthma: Asthma diagnosis by year 3 (ever having asthma) (diagnosis by a physician, parent-reported)Measure of frequencyIncidenceExposureSystemic ABX us: antibiotic use during pregnancyOperationalizationPrenatal ABX use: dichotomous (yes/no) (any ABX during pregnancy)exposureTiming of ABX use (first trimester vs. second and third trimester)Measurement exposureQuestionnaires"(Study) design"?Yes (discussion)Data collection designCohort (discussion) Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)T0At 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; any ibuprofen use of the dild's first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of the child's first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of life; smoking in the home during the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders?No	litie	
development of asthma by year 3 and wheezing in the third year"DomainAt-risk children up to the age of 3 years (title & discussion)OutcomeAsthma: Asthma diagnosis by year 3 (ever having asthma) (diagnosis by a physician, parent-reported)Measure of frequencyIncidenceExposureSystemic ABX us: antibiotic use during pregnancyOperationalizationPrenatal ABX use: dichotomous (yes/no) (any ABX during pregnancy)exposureTiming of ABX use (first trimester vs. second and third trimester)Measurement exposureQuestionnaires"(Study) design"?Yes (discussion)Data collection designCohort (discussion) Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)T0At 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; any ibuprofen use during the child's first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; child antibiotic use of the child in the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders?NoReporting guideline orNo	A	
DomainAt-risk children up to the age of 3 years (title & discussion)OutcomeAsthma: Asthma diagnosis by year 3 (ever having asthma) (diagnosis by a physician, parent-reported)Measure of frequencyIncidenceExposureSystemic ABX us: antibiotic use during pregnancyOperationalizationPrenatal ABX use: dichotomous (yes/no) (any ABX during pregnancy)exposureTiming of ABX use (first trimester vs. second and third trimester)Measurement exposureQuestionnaires"(Study) design"?Yes (discussion)Data collection designCohort (discussion)Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)ToAt 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal age; smoking during pregnancy; any ibuprofen use during pregnancy; maternal age; smoking during pregnancy; any ibuprofen use during the child's first year of life; child antibiotic use for respiratory reasons, vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; smoking in the home during the child's first year of lifeEffect modifiersVitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; first year of life; smoking in the home during the child's first year of lifeIster to avail the first year of life; smoking in the home during the child's first year of lifeEffect modifiers?No	AIM	
OutcomeAsthma: Asthma diagnosis by year 3 (ever having asthma) (diagnosis by a physician, parent-reported)Measure of frequencyIncidenceExposureSystemic ABX us: antibiotic use during pregnancyOperationalizationPrenatal ABX use: dichotomous (yes/no) (any ABX during pregnancy)exposureTiming of ABX use (first trimester vs. second and third trimester)Measurement exposureQuestionnaires"(Study) design"?Yes (discussion)Data collection designCohort (discussion) Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)TOAt 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; any ibuprofen use during the child's first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of the child's first year of life; sany respiratory infections during the child's first year of life; smoking in the home during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; thirdren who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders?NoReporting guideline orNo		
physician, parent-reported)Measure of frequencyIncidenceExposureSystemic ABX us: antibiotic use during pregnancyOperationalizationPrenatal ABX use: dichotomous (yes/no) (any ABX during pregnancy)exposureTiming of ABX use (first trimester vs. second and third trimester)Measurement exposureQuestionnaires('study) design'?Yes (discussion)Data collection designCohort (discussion)Prospective study (Introduction)Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)TOAt 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; any ibuprofen use during the child's first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of life; siny use of the child in the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of life; smoking in the home during the child's first year of life; smoking in the home during the child's first year of life; smoking in the home during the child's first year of lifeIstification selection confounders/effect modifiers?No		
Measure of frequencyIncidenceExposureSystemic ABX us: antibiotic use during pregnancyOperationalizationPrenatal ABX use: dichotomous (yes/no) (any ABX during pregnancy)exposureTiming of ABX use (first trimester vs. second and third trimester)Measurement exposureQuestionnaires"(Study) design"?Yes (discussion)Data collection designCohort (discussion)Prospective study (Introduction)Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)T0At 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; exposure to smoke in the home in the first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use during the child's first year of life; smoking during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; sing very of life; sing very of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of life; smoking in the home during the child's first year of life; smoking in the home during the child's first year of life; smoking in the home during the child's first year of life; smoking in the home during the child's first year of life; smoking in the home during the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?No	Outcome	
ExposureSystemic ABX us: antibiotic use during pregnancyOperationalization exposurePrenatal ABX use: dichotomous (yes/no) (any ABX during pregnancy)Timing of ABX use (first trimester vs. second and third trimester)Measurement exposureQuestionnaires"(Study) design"?Yes (discussion)Data collection designCohort (discussion)Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)T0At 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; any ibuprofen use during the child's first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of life; sing intervention; maternal history of asthma; any ibuprofen use of the child in the first year of life; sing the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of life; bustification selection confounders/effect modifiers?NoJustification selection confounders/effect modifiers?No		
Operationalization exposurePrenatal ABX use: dichotomous (yes/no) (any ABX during pregnancy) Timing of ABX use (first trimester vs. second and third trimester)Measurement exposure "(Study) design"?QuestionnairesWes (discussion) Data collection designCohort (discussion) Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)T0At 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; waternal age; smoking during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of life; any ispiratory infections during the child's first year of life; any ibuprofen use of the child in the first year of life; smoking in the home during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; smoking in the home during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?No		
exposureTiming of ABX use (first trimester vs. second and third trimester)Measurement exposureQuestionnaires"(Study) design"?Yes (discussion)Data collection designCohort (discussion) Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)TOAt 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; exposure to smoke in the home in the first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of life; any ispiratory infections during the child's first year of life; smoking in the home during pregnancy; infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?NoReporting guideline orNo	-	
Measurement exposureQuestionnaires"(Study) design"?Yes (discussion)Data collection designCohort (discussion)Prospective study (Introduction)Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)T0At 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; exposure to smoke in the home in the first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of lifeEffect modifiersVitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?No	Operationalization	
"(Study) design"?Yes (discussion)Data collection designCohort (discussion) Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)T0At 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; exposure to smoke in the home in the first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of lifeEffect modifiersVitamin use of the mother during pregnancy; internal history of asthma; any ibuprofen use of the child in the first year of life; smoking in the home during the child's first year of life; smoking in the home during the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?No	exposure	
Data collection designCohort (discussion) Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)T0At 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; exposure to smoke in the home in the first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of lifeEffect modifiersVitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders?NoReporting guideline orNo	Measurement exposure	Questionnaires
Prospective study (Introduction)Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)T0At 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; exposure to smoke in the home in the first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of lifeEffect modifiersVitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?NoReporting guideline orNo	"(Study) design"?	Yes (discussion)
Data analysis designMultivariable logistic regressionMeasure of associationOR (results, per category)T0At 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; exposure to smoke in the home in the first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of lifeEffect modifiersVitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?NoReporting guideline orNo	Data collection design	Cohort (discussion)
Measure of associationOR (results, per category)TOAt 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; exposure to smoke in the home in the first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of lifeEffect modifiersVitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; child not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?NoReporting guideline orNo		Prospective study (Introduction)
T0At 1 year of age (implicitly)ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; exposure to smoke in the home in the first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of lifeEffect modifiersVitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?NoReporting guideline orNo	Data analysis design	Multivariable logistic regression
ConfoundersStudy intervention; maternal history of asthma; maternal ethnicity (Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; exposure to smoke in the home in the first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of lifeEffect modifiersVitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; child anti use of the child in the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?NoReporting guideline orNo	Measure of association	OR (results, per category)
(Mexican ancestry); ibuprofen use during pregnancy; maternal age; smoking during pregnancy; exposure to smoke in the home in the first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of lifeEffect modifiersVitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?NoReporting guideline orNo	то	At 1 year of age (implicitly)
smoking during pregnancy; exposure to smoke in the home in the first year of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of lifeEffect modifiersVitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?NoReporting guideline orNo	Confounders	Study intervention; maternal history of asthma; maternal ethnicity
of life; child antibiotic use for respiratory reasons; vitamin use of the mother during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of lifeEffect modifiersVitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?NoReporting guideline orNo		(Mexican ancestry); ibuprofen use during pregnancy; maternal age;
mother during pregnancy; any ibuprofen use during the child's first year of life; any respiratory infections during the child's first year of lifeEffect modifiersVitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?NoReporting guideline orNo		smoking during pregnancy; exposure to smoke in the home in the first year
life; any respiratory infections during the child's first year of lifeEffect modifiersVitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?NoReporting guideline orNo		of life; child antibiotic use for respiratory reasons; vitamin use of the
Effect modifiersVitamin use of the mother during pregnancy; maternal history of asthma; any ibuprofen use of the child in the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?NoReporting guideline orNo		mother during pregnancy; any ibuprofen use during the child's first year of
any ibuprofen use of the child in the first year of life; children who did not use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of lifeJustification selection confounders/effect modifiers?NoReporting guideline orNo		life; any respiratory infections during the child's first year of life
use ABX in the first year of life; respiratory infections in the child's first year of life; smoking in the home during the child's first year of life         Justification selection confounders/effect modifiers?       No         Reporting guideline or       No	Effect modifiers	Vitamin use of the mother during pregnancy; maternal history of asthma;
of life; smoking in the home during the child's first year of life         Justification selection       No         confounders/effect       Head of the selection         modifiers?       No         Reporting guideline or       No		any ibuprofen use of the child in the first year of life; children who did not
Justification selection     No       confounders/effect     modifiers?       Reporting guideline or     No		use ABX in the first year of life; respiratory infections in the child's first year
Justification selection     No       confounders/effect     modifiers?       Reporting guideline or     No		
modifiers?       Reporting guideline or     No	Justification selection	No
Reporting guideline or No	confounders/effect	
	•	
	Reporting guideline or	No

#### 20. The relationship between prenatal antibiotic use and asthma in at-risk children. Lapin et al.

#### **Theoretical design:**

Future incidence of asthma onset as a function of baseline (1 year of age) exposure profile (maternal ABX use during pregnancy) in children up to the age of 3 years adjusted for confounding by study intervention, maternal history of asthma, maternal ethnicity (Mexican ancestry), ibuprofen use during pregnancy, maternal age, smoking during pregnancy, exposure to smoke in the home in the first year of life, child antibiotic use for respiratory reasons, vitamin use of the mother during pregnancy, any ibuprofen use during the child's first year of life, any respiratory infections during the child's first year of life and effect modification by vitamin use of the mother during pregnancy, maternal history of asthma, any ibuprofen use of the child in the first year of life, children who did not use ABX in the first year of life, respiratory infections in the child's first year of life and smoking in the home during the child's first year of life and smoking in the home

45. Antibiotic use in infancy and symptoms of asthma, rhinoconjunctivitis, and eczema in children 6 and 7 years old: International study of asthma and allergies in childhood phase III. Foliaki et al.

Number	45
Reference	Foliaki et al.
Journal	J Allergy Clin Immunol
ҮОР	2009
IF	9.1
Title	Antibiotic use in infancy and symptoms of asthma, rhinoconjunctivitis, and
	eczema in children 6 and 7 years old: International study of asthma and
	allergies in childhood phase III
Aim	"to study the associations between parental-reported ABX use in the first
	year of life and current symptoms of asthma, rhinoconjunctivitis, and
	eczema in children 6 and 7 years old"
Domain	Children aged 6-7 years (title, introduction, methods, results & discussion)
Outcome	Severe asthma symptoms: ('current') wheezing causing sleep disturbance,
	or wheezing limiting speech, or at least 4 attacks of wheezing in the past 12
	months
	Asthma ever
Measure of frequency	/
Exposure	ABX use in the first year of life
Operationalization	Dichotomous (Yes/No)
exposure	
Measurement exposure	ISAAC questionnaire
"(Study) design"?	No
Data collection design	Cross-sectional study (discussion)
Data analysis design	Generalized linear mixed models
	Multiple regression analysis
Measure of association	Prevalence odds ratio's (methods, one OR for asthma)
ТО	6-7 years of age (implicitly)
Confounders	Sex; language; maternal education; ever breast fed; current diet (at 6-7
	years of age); region (not specified); gross national income (not specified);
	paracetamol use first year of life; parental smoking (not specified); siblings
	(not specified)
Effect modifiers	/
Justification selection	No
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	

# Theoretical design:

Current prevalence of asthma at as a function of baseline (6-7 years if age) exposure profile (ABX use in the first year of life) in 6 to 7 year old children adjusted for confounding by sex, language, ever breast fed (first year of life), paracetamol use (first year of life), maternal education, region (not specified), gross national income (not specified); parental smoking (not specified), siblings (not specified) and current diet (at 6-7 years of age).

46. Cross-sectional survey of risk factors for asthma in 6-7 year-old children in New Zealand: International study of asthma and allergies in childhood phase three. Mitchell et al.

Number	46
Reference	Mitchell et al.
Journal	Journal of Pediatrics and Child Health
YOP	2009
IF	1.1
Title	Cross-sectional survey of risk factors for asthma in 6-7 year-old children in
	New Zealand: International study of asthma and allergies in childhood
	phase three
Aim	"to identify and quantify risk factors for asthma in over 10000 6-7-year-
	old children"
Domain	Children aged 6-7 years (title, introduction, methods, results & discussion)
Outcome	Wheeze in the last 12 months (6-7 years, 'current' wheeze)
Measure of frequency	Prevalence
Exposure	ABX in the first year of life
Operationalization	Dichotomous (Yes/No)
exposure	
Measurement exposure	ISAAC questionnaire at 6-7 years
"(Study) design"?	No
Data collection design	Cross-sectional survey (abstract & discussion)
Data analysis design	Logistic regression
Measure of association	OR (results, 1 OR for asthma)
то	6-7 years of age (implicitly)
Confounders	Gender; school decile (at 6-7 years of age); maternal farm animal exposure during pregnancy; born in New Zealand; number of older siblings (at 6-7 years of age); number of younger siblings (at 6-7 years of age); contact farm animals in first year; paracetamol use in first year; current paternal and maternal smoking (at 6-7 years of age); cooking appliance (at 6-7 years of age); television viewing (at 6-7 years of age); ethnicity; maternal education (at 6-7 years of age); breast feeding (first year of life); maternal smoking first year; cat at home in the first year; dog at home in the first year; food intake (at 6-7 years of age); truck passage street (at 6-7 years of age); physical activity (at 6-7 years of age)
Effect modifiers	/
Justification selection	No
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	

#### **Theoretical design:**

Current prevalence of wheeze as a function of baseline (6-7 years of age) exposure profile (ABX use in the first year of life) in children aged 6-7 years adjusted for confounding by gender, ethnicity, maternal farm animal exposure (during pregnancy), born in New Zealand, contact farm animals (first year of life), paracetamol use (first year of life), breast feeding (first year of life), maternal smoking (first year of life), cat at home (first year of life), dog at home (first year of life), school decile (at 6-7 years of age), number of older siblings (at 6-7 years of age), number of younger siblings (at 6-7 years of age), current paternal and maternal smoking (at 6-7 years of age), cooking appliance (at 6-7 years of age), television viewing (at 6-7

7 years of age), maternal education (at 6-7 years of age), food intake (at 6-7 years of age), truck passage street (at 6-7 years of age) and physical activity (at 6-7 years of age).

#### 47. Antibiotic use in children is associated with increased risk of asthma. Marra et al.

Number	47
Reference	Marra et al.
Journal	Pediatrics
YOP	2009
IF	4.6
Title	Antibiotic use in children is associated with increased risk of asthma
Aim	"to explore the association between exposure to ABX in the first year of life and the subsequent development of asthma Specifically we sought to evaluate the association between antibiotics prescribed within the first year of life and the development of asthma, and to evaluate a potential dose- response relationship between the number of courses of antibiotics received and the development of asthma."
Domain	Children (title, introduction, results & discussion)
Outcome	Asthma diagnosis: hospital discharge for asthma or 2 medical fee-for- service claims within a moving 12-months period or 2 prescriptions for a known asthma medication within a moving 12-months period
Measure of frequency	Incidence
Exposure	Exposure to ABX in the first year of life
Operationalization	Dichotomous (Ever/Never)
exposure	Number of ABX prescriptions (4 levels)
	Type of antibiotic dispensed (6 categories)
Measurement exposure	Administrative health data (database)
"(Study) design"?	Yes (discussion)
Data collection design	Longitudinal cohort study (methods) Observational prospective cohort study (discussion)
Data analysis design	Cox proportional hazard
Measure of association	HR
	Incidence rate asthma
	(methods, HR for development of asthma for every category of exposure)
то	At 1 year of age (implicitly)
Confounders	Gender; SES at birth; urban or rural address at birth; birth weight; gestational age; delivery method; frequency of physician visits (first year of life); allergist/respirologist/immunologist visit (first year of life); hospital visit involving surgery (first year of life); congenital anomalies (first year of life); related diseases (otitis media/bronchitis/URTI and LRTI; first year of life)
Effect modifiers	/
Justification selection confounders/effect modifiers?	No
Reporting guideline or theoretical work?	No

#### **Theoretical design:**

Future incidence of asthma onset as a function of baseline (at 1 year of age) exposure profile (ABX use in the first year of life) in children adjusted for confounding by gender, birth weight, gestational age, delivery method, SES at birth, urban or rural address at birth, frequency of physician visits (first year of life), allergist/respirologist/immunologist visit (first year of life), hospital visit involving surgery (first year of life), congenital anomalies (first year of life) and related diseases (otitis media; bronchitis; URTI and LRTI) (first year of life).

#### 48. Antibiotic use in the first year of life and risk of atopic disease in early childhood. Kusel et al.

Number	48
Reference	Kusel et al.
Journal	Clinical and Experimental Allergy
YOP	2008
IF	3.6
Title	Antibiotic use in the first year of life and risk of atopic disease in early childhood
Aim	<i>"to investigate the association between ABX use in the first year of life and the development of atopic disease at 5 years."</i>
Domain	Preschool children at high risk for atopy (introduction, methods & discussion)
Outcome	'Current' asthma: doctor's diagnosis of asthma & 'current' wheeze between 4-5 years of age Atopic 'current' asthma: 'current' asthma + positive SPT at 5 years or elevated serum total IgE at 5 years
Measure of frequency	/
Exposure	ABX use in the first year of life
Operationalization	Categorical (ABX use 0-6 months, 7-12 months and 1-12 months)
exposure	
Measurement exposure	Daily diary
"(Study) design"?	No
Data collection design	High-risk birth cohort (introduction & discussion) Prospective birth cohort (abstract)
Data analysis design	Propensity score adjustment Logistic regression
Measure of association	OR (results, OR for asthma for every category of ABX exposure)
то	At 1 year of age (implicitly)
Confounders	Propensity score (antibiotic predictor group); number of doctor's visits; sex; childcare (first year of life); pets (first year of life)
Effect modifiers	Number of doctor's visits (first year of life); sex; childcare (first year of life); pets (first year of life); ABX use between 0-6 months
Justification selection confounders/effect modifiers?	No
Reporting guideline or theoretical work?	No

#### **Theoretical design:**

Future prevalence of 'current' asthma/atopic 'current' asthma as a function of baseline (at 1 year of age) exposure profile (ABX use in the first year of life) in preschool children at high risk for atopy adjusted for confounding by propensity score (antibiotics predictor group), sex, childcare (first year of life), pets (first year of life), number of doctor's visits (unspecified) ) and effect modification by sex, ABX use (between 0-6 months of age), childcare (first year of life) and number of doctor's visits (unspecified).

49. Determinants of the incidence of childhood asthma: a two-stage case-control study. Martel et al.

Number	49
Reference	Martel et al.
Journal	Am J Epidemiol
YOP	2008
IF	5.4
Title	Determinants of the incidence of childhood asthma: a two-stage case- control study
Aim	" identifying the independent effects of 47 potential predictors, measured during pregnancy and after birth, on the incidence of asthma development in children within the first 10 years of life."
Domain	Children up to the age of 10 years (introduction, methods, results & discussion)
Outcome	Childhood asthma: at least 1 diagnosis of asthma and at least 1 prescription for asthma medication within a 2-year period
Measure of frequency	Incidence
Exposure	Mean number of ABX prescriptions filled per month during pregnancy ABX in the first 6 months of life or ABX prior to index date
Operationalization	Dichotomous for ABX use child (Yes/No)
exposure	Not clear how they coded the variable for the mother
Measurement exposure	From administrative linked health databases
"(Study) design"?	Yes (methods)
Data collection design	Case-control study, nested in a cohort of children (methods)
	Two-stage case-control study (title, abstract & methods)
Data analysis design	Conditional logistic regression
Measure of association	Rate ratio's (methods, 1 rate ratio for ABX exposure in child, 1 rate ratio for ABX exposure in pregnancy, RR per additional prescription) OR (idem)
то	First occurrence of an asthma diagnosis (code) and a filled prescription for asthma medication within a 2 year period: refer to this as index date (explicitly)
Confounders	Age at diagnosis; gender; allergic disease prior to index date; administration of oxygen to newborn in hospital; one or more diagnoses of bronchopulmonary disease (prior to index date); maternal receipt of social welfare (in year before or during pregnancy); intranasal corticosteroids during pregnancy; paternal history of asthma; presence of wood-burning fireplace in home (prior to index date); day-care attendance (prior to index date); pets in the home (for more than 2 months) (prior to index date); breast feeding; asthma during pregnancy; asthma siblings (prior to index date)
Effect modifiers	/
Justification selection confounders/effect modifiers?	No
Reporting guideline or theoretical work?	No

# **Theoretical design:**

Current incidence of asthma as a function of baseline (first occurrence of an asthma diagnosis (code) and a filled prescription for asthma medication within a 2 year period) exposure profile (maternal exposure to ABX prescriptions filled during pregnancy/ ABX use in

the first 6 months of life or prior to index date) in children up to the age of 10 years adjusted for confounding by gender, intranasal corticosteroids during pregnancy, asthma during pregnancy, administration of oxygen to newborn in hospital, age at diagnosis, allergic disease prior to index date, presence of wood-burning fireplace in home prior to index date, day-care attendance prior to index date, pets in home (for more than 2 months) prior to index date, asthma siblings (prior to index date), one or more diagnoses of bronchopulmonary disease (prior to index date); maternal receipt of social welfare (in year before or during pregnancy), paternal history of asthma (prior to index date) and breast feeding. 50. The association of early life exposure to antibiotics and the development of asthma, eczema and atopy in a birth cohort: confounding or causality? Wickens et al.

Number	50
Reference	Wickens et al.
Journal	Clinical and Experimental Allergy
YOP	2008
IF	3.6
Title	The association of early life exposure to antibiotics and the development of
	asthma, eczema and atopy in a birth cohort: confounding or causality?
Aim	"to investigate the relationship between ABX and the subsequent
	development of asthma, eczema and atopy A secondary aim was to
	determine whether this association is due to confounding by chest
	infections in infancy."
Domain	Children (introduction & methods)
Outcome	'Current' asthma: asthma + wheeze and/or inhaler use occurring in the
	previous 12 months
Measure of frequency	Prevalence
Exposure	ABX use: ever in the first 3 months
	ABX use: between 3 and 15 months
Operationalization	3 categories: systemic ABX use, 1 chest infections, 2+ chest infection for 3
exposure	months, 15 months and 4 years
Measurement exposure	Questionnaire at 3 and 15 months of age
"(Study) design"?	No
Data collection design	Prospective study (discussion)
	Birth cohort study (abstract)
	Cohort (discussion)
Data analysis design	Cross-sectional associations
, ,	Multivariate logistic regression
Measure of association	OR (results, OR for both outcomes per category of exposure)
то	Asthma diagnosis period (implicitly)
Confounders	Number of chest infections (0-4 years of age); gender; prioritized ethnicity;
	family history of asthma, eczema/hay fever; ABX use during outcome
	period; household smoking (any by father or mother); ear infection (0-4
	years of age); parity (before 3 months of age)
Effect modifiers	Number of chest infections (0-4 years of age)
Justification selection	No
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	

#### **Theoretical design:**

Current prevalence of 'current' asthma (between 0-15 months of age/between 3-4 years of age) as a function of baseline (asthma diagnosis period) exposure profile (ABX use before 3 months of age/ABX use between 3-15 months of age/ ABX use before 4 years of age) in children adjusted for confounding by gender, prioritized ethnicity (before 3 months of age), parity (before 3 months of age), ABX use during outcome period, number of chest infections (0-4 years of age), ear infection (0-4 years of age), family history of asthma, eczema or hay fever (family history), household smoking (any by father or mother) and effect modification by number of chest infections (0-4 years of age).

# 51. Risk factors for asthma at 3.5 and 7 years of age. Mitchell et al.

Number	51
Reference	Mitchell et al.
Journal	Clinical and Experimental Allergy
YOP	2007
IF	3.7
Title	Risk factors for asthma at 3.5 and 7 years of age
Aim	"to examine risk factors for asthma in children aged 3.5 and 7 years of
AIIII	age, with particular emphasis on environmental exposures in infancy
	including birth weight, maternal smoking, breast feeding, day care, ABX
	treatment and exposure to inhaled allergens."
Domain	Children aged 3.5 and 7 years of age (introduction, methods, results &
2011011	discussion)
Outcome	'Current' wheeze (past 12 months): asthma at 3.5 and 7 years of age
Measure of frequency	Prevalence
Exposure	ABX in the first year of life
Operationalization	Dichotomous (Yes/No)
exposure	
Measurement exposure	Questionnaire at 3.5 years of age
"(Study) design"?	Yes (methods & discussion)
Data collection design	Prospective study (discussion)
Data analysis design	Generalized linear models
	Logistic regression
Measure of association	OR (methods, OR for exposure yes vs. no)
ТО	At 1 year of age / asthma onset (at 3.5 or 7 years of age) (implicitly)
Confounders	Age (at inclusion); smoking (pregnancy); day care or looked after by others
	(first year of life); presence of dog (first year of life); used pillow (first year
	of life); used quilt (first year of life); slept on used mattress (first year of
	life); hospitalized (first year of life); asthma in parents (current); maternal
	smoking (current); eczema in child (current); rhinitis in child (current);
	positive skin test in child (current); gender; SGA (at birth); first born (at
	birth); SES (at birth); damp patches on walls in winter (first year of life);
	fungus/mould all year (first year of life); presence of cat (first year of life);
	presence of bird (first year of life); slept on sheepskin (first year of life);
	children in household (at 1 year); duration of breast feeding (first year of
	life); carpet in bedroom (first year of life); trucks passing house frequently
Effect modifiers	(7 years of age) Interaction with age (at inclusion) and significant factors: presence of dog
Enect modifiers	(first year of life); maternal smoking during pregnancy; used quilt (first year
	of life); slept on used mattress (first year of life); hospitalization (first year
	of life); parental asthma; eczema in child (current); rhinitis in child
	(current); positive skin test in child (current); current maternal smoking;
	day care or looked after by others (first year of life)
Justification selection	No
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	
	1

Theoretical design: 2 possibilities

Future prevalence of 'current' wheeze as a function of as a function of baseline (at 1 year of age) exposure profile (ABX use in the first year of life) in children aged 3.5 and 7 years of age

for confounding by age (at inclusion), smoking (pregnancy), day care or looked after by others (first year of life), presence of dog (first year of life), used pillow (first year of life), used quilt (first year of life), slept on used mattress (first year of life), hospitalized (first year of life), asthma in parents (current), maternal smoking (current), eczema in child (current), rhinitis in child (current), positive skin test in child (current), gender, SGA (at birth), first born (at birth), SES (at birth), damp patches on walls in winter (first year of life), fungus/mould all year (first year of life), presence of cat (first year of life), presence of bird (first year of life), slept on sheepskin (first year of life), children in household (at 1 year), duration of breast feeding (first year of life), carpet in bedroom (first year of life), trucks passing house frequently (7 years of age) and effect modification by age, presence of dog (first year of life), maternal smoking during pregnancy, used quilt (first year of life), slept on used mattress (first year of life), hospitalization (first year of life), parental asthma, eczema in child (current), rhinitis in child (current), positive skin test in child (current), current maternal smoking and day care or looked after by others (first year of life).

Current prevalence of 'current' wheeze as a function of baseline (asthma onset at 3.5 or 7 years of age) exposure profile (ABX use in the first year of life) in children aged 3.5 and 7 years of age adjusted for confounding by age (at inclusion), smoking (pregnancy), day care or looked after by others (first year of life), presence of dog (first year of life), used pillow (first year of life), used quilt (first year of life), slept on used mattress (first year of life), hospitalized (first year of life), asthma in parents (current), maternal smoking (current), eczema in child (current), rhinitis in child (current), positive skin test in child (current), gender, SGA (at birth), first born (at birth), SES (at birth), damp patches on walls in winter (first year of life), fungus/mould all year (first year of life), presence of cat (first year of life), presence of bird (first year of life), slept on sheepskin (first year of life), children in household (at 1 year), duration of breast feeding (first year of life), carpet in bedroom (first year of life), trucks passing house frequently (7 years of age) and effect modification by age, presence of dog (first year of life), maternal smoking during pregnancy, used quilt (first year of life), slept on used mattress (first year of life), hospitalization (first year of life), parental asthma, eczema in child (current), rhinitis in child (current), positive skin test in child (current), current maternal smoking and day care or looked after by others (first year of life).

#### 52. Increased risk of childhood asthma from antibiotics use in early life. Kozyrskyj et al.

Number	52
Reference	Kozyrskyj et al.
Journal	Chest
YOP	2007
IF	4.1
Title	Increased risk of childhood asthma from antibiotics use in early life
Aim	
Aim	"examine the association between oral ABX use in the first year of life and
Domain	asthma at age 7 years"
Domain	Children 7 years of age (introduction, methods, results & discussion)
Outcome	'Current' asthma at age 7: at least 2 physician visits for asthma, 1 asthma
	hospitalization or 2 prescriptions for any asthma drug in the year following
	the 7 <sup>th</sup> birthday
Measure of frequency	Prevalence
Exposure	ABX use during the first year of life (number of oral ABX prescriptions)
Operationalization	Number of oral ABX prescriptions (4 categories)
exposure	
Measurement exposure	Health-care administrative data
"(Study) design"?	Yes (introduction)
Data collection design	Longitudinal study (abstract & methods)
	Cohort (discussion)
Data analysis design	Multivariate logistic regression
Measure of association	OR (results, for each category of exposure OR for outcome)
то	At 1 year of age / at 7 years of age (implicitly)
Confounders	Gender; maternal history of asthma; number of health care visits (first year
	of life); number of non-respiratory tract infections (unspecified); number of
	siblings (at 7 years of age); urban/rural location (unspecified); number of
	LRTI (unspecified); household income (unspecified)
Effect modifiers	Maternal history of asthma; presence or absence of dog during birth year
	(during birth year); urban/rural location (unspecified)
Justification selection	No
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	

#### Theoretical design: 2 possibilities

Future prevalence of 'current' asthma as a function of baseline (at 1 year of age) exposure profile (ABX use in the first year of life) in children 7 years of age adjusted for confounding by gender, maternal history of asthma, number of non-respiratory tract infections (unspecified), urban/rural location (unspecified), household income (unspecified), number of LRTI (unspecified), number of health care visits (first year of life), number of siblings (at 7 years of age) and effect modification by maternal history of asthma, urban/rural location (unspecified) and presence or absence of dog (during birth year).

<u>Current prevalence of 'current' asthma as a function of baseline (at 7 years of age)</u> <u>exposure profile (ABX use in the first year of life) in children 7 years of age adjusted for</u> <u>confounding by gender, maternal history of asthma, number of non-respiratory tract</u> <u>infections (unspecified), urban/rural location (unspecified), household income</u> (unspecified), number of LRTI (unspecified), number of health care visits (first year of life), number of siblings (at 7 years of age) and effect modification by maternal history of asthma, urban/rural location (unspecified) and presence or absence of dog (during birth year).

53. Identification of asthma risk factors in Mexico City in an International Study of Asthma and Allergy in Childhood survey. Del-Rio-Navarro et al.

Number	53
Reference	Del-Rio-Navarro et al.
Journal	Allergy and Asthma Proceedings
YOP	2006
IF	0.75
Title	Identification of asthma risk factors in Mexico City in an International Study
	of Asthma and Allergy in Childhood survey
Aim	"perform a risk analysis based on the ISAAC survey in Mexico."
Domain	Childhood (6-7 years of age and 13-14 years of age) (methods, results &
	discussion)
Outcome	Cumulative prevalence of asthma (wheezing ever)
	Current prevalence of asthma (wheezing last 12 months)
Measure of frequency	Cumulative prevalence
	Current prevalence
Exposure	ABX use in the first year of life
Operationalization	Dichotomous (Yes/No)
exposure	
Measurement exposure	ISAAC questionnaire at age 6-7 years old
"(Study) design"?	No
Data collection design	Cross-sectional survey (methods)
Data analysis design	Logistic regression using the forward conditional method
Measure of association	OR (one OR for exposure related to asthma, results)
то	6-7 years of age and 13-14 years of age (implicitly)
Confounders	/
Effect modifiers	
Justification selection	No
confounders/effect	
modifiers?	
Reporting guideline or	No
theoretical work?	

#### **Theoretical design:**

Current prevalence of asthma/cumulative prevalence of asthma as a function of baseline (6-7 years of age/13-14 years of age) exposure profile (ABX use in the first year of life) in children aged 6-7 years of age and 13-14 years of age.

#### 54. Allergic disease and sensitization in Steiner school children. Floïstrup et al.

Number	54
Reference	Floïstrup et al.
Journal	J Allergy Clin Immunol
YOP	2005
IF	7.7
Title	Allergic disease and sensitization in Steiner school children
Aim	"to identify possible protective factors for allergy associated with the anthroposophic lifestyle"
Domain	Children aged 5 to 13 years (title, introduction, methods, results & discussion)
Outcome	Doctor's diagnosis of asthma: ever asthma diagnosis
Measure of frequency	Prevalence
Exposure	Use of ABX in the first year of life
Operationalization	Never/first use after 12 months of age and first use first 12 months of age
exposure	
Measurement exposure	Parental questionnaire among children age 5-13 years
"(Study) design"?	Yes (discussion & methods)
Data collection design	Cross-sectional (abstract, methods & discussion)
Data analysis design	Logistic regression
Measure of association	OR (methods, for every category of ABX exposure)
ТО	5-13 years of age / 1 year of age (implicitly)
Confounders	Age (at inclusion in the study); sex; country; maternal smoking during pregnancy; maternal asthma and/or rhinoconjunctivis; paternal asthma and/or rhinoconjunctivis; having household pets during the first year of life; use of antipyretics during the first year of life; measles infection (not specified); type of diet (not specified); MMR vaccination; current smoking in the household; older siblings; parental education
Effect modifiers	/
Justification selection confounders/effect modifiers?	Yes: referral to previous results in other publication
Reporting guideline or theoretical work?	No

Theoretical design: 2 possibilities

Current prevalence of asthma as a function of baseline (at 5-13 years of age) exposure profile (ABX use in the first year of life) in children aged 5-13 years of age adjusted for confounding by age (at inclusion in the study), sex, country, maternal smoking during pregnancy, maternal asthma and/or rhinoconjunctivis, paternal asthma and/or rhinoconjunctivis, having household pets during the first year of life, use of antipyretics during the first year of life, measles infection (not specified), type of diet (not specified), MMR vaccination, current smoking in the household, older siblings and parental education.

Future prevalence of asthma as a function of baseline (at 1 year of age) exposure profile ( ABX use in the first year of life) in children aged 5-13 years of age adjusted for confounding by age (at inclusion in the study), sex, country, maternal smoking during pregnancy, maternal asthma and/or rhinoconjunctivis, paternal asthma and/or rhinoconjunctivis, having household pets during the first year of life, use of antipyretics during the first year of life, measles infection (not specified), type of diet (not specified), MMR vaccination, current smoking in the household, older siblings and parental education.